Quest Diagnostics prices $1.85B in senior notes to fund LifeLabs acquisition

QUEST DIAGNOSTICS INC

Issued $400M at 4.600% due 2027, $600M at 4.625% due 2029, $850M at 5.000% due 2034.
Net proceeds to fund LifeLabs purchase price and related costs, plus general corporate purposes.
2027 and 2029 notes subject to special mandatory redemption at 101% if LifeLabs deal not completed.
2034 notes will remain outstanding even if LifeLabs acquisition is not consummated.
By-laws amended to provide officer exculpation as permitted by Delaware law.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.